Tesaro's PARP ovarian cancer drug hits PhIII goal; prepares to file - FierceBiotech

FierceBiotech

Tesaro's PARP ovarian cancer drug hits PhIII goal; prepares to file FierceBiotech Tesaro ($TSRO) has posted positive top-line results for its experimental PARP inhibitor niraparib for patients who express BRCA--and those who don't--as it looks to file later this year. The Waltham, MA-based biotech said its Phase III trial for ... TESARO (TSRO) Phase 3 NOVA Trial of Niraparib Achieves Primary EndpointStreetInsider.com Tesaro's Cancer Drug Meets Primary Endpoint in Late-Stage TrialWall Street Journal Tesaro's ovarian cancer drug shows benefit in late-stage trialReuters all 4 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNF5nk2vTDMjXMPF1BhesX9OQqFz-w&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779143737877&ei=gLVzV8CXDczH3gHnl7SgCQ&url=http://www.fiercebiotech.com/biotech/tesaro-s-parp-ovarian-cancer-drug-hits-phiii-goal-prepares-to-file
via IFTTT